Traditional Chinese medicine composition and preparation method thereof
By developing a traditional Chinese medicine composition composed of mung beans, Bupleurum, Yinchen, isatis root, Schisandra chinensis, pig bile powder and cockscomb, the broad spectrum and side effects of existing antiviral drugs have been solved, and a variety of viruses have been achieved effective inhibition and immune system enhancement.
Patent Information
- Application Number
- CN202411024319.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
AI Technical Summary
Existing antiviral drugs lack broad spectrum, have drug resistance and side effects, and are difficult to effectively target multiple viruses and are toxic to normal human cells.
Develop a traditional Chinese medicine composition consisting of mung beans, Bupleurum, Yinchen, isatis root, Schisandra chinensis, pig bile powder and cockscomb. It is made of antiviral oral powder through specific compatibility ratios and preparation methods, and has antiviral properties for a variety of viruses. active.
This traditional Chinese medicine composition has broad-spectrum antiviral activity and has few side effects. It can inhibit multiple viral infections at the same time, reduce virus resistance, enhance the body's immune system, and improve treatment effect.
Smart Images

Figure SMS_13 
Figure HDA0004968111590000011 
Figure HDA0004968111590000021
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition and a preparation method thereof. Background Art
[0002] Viral infections are a common public health problem that can cause serious illness or even death. Viruses can be easily transmitted through contact, breathing, or the digestive tract. At the same time, viruses can mutate rapidly, which makes them difficult to treat and prevent. Mutations can cause viruses to be more contagious, pathogenic, and drug-resistant. There are many known types of viruses, and new strains of viruses continue to emerge, posing a major threat to human health. Existing antiviral drugs mainly target specific viruses and have problems such as drug resistance, side effects, and poor efficacy. Moreover, antiviral drugs are usually only effective against a few types of viruses and lack broad-spectrum properties; at the same time, existing antiviral drugs usually lack targeting and are prone to toxic side effects on normal cells in the human body. Therefore, the development of drugs that are effective against broad-spectrum viruses with fewer side effects is an important topic in today's medical research field.
[0003] Traditional Chinese medicine has a long history and rich experience. It has unique advantages in antiviral treatment and plays an important role. Traditional Chinese medicine has multiple pharmacological effects such as antiviral and immune enhancement, and has relatively few side effects. The combination of traditional Chinese medicine has the advantages of synergistic enhancement and reduced toxic side effects. By rationally combining traditional Chinese medicines, the antiviral effect can be improved, the side effects can be reduced, and the safety of the drugs can be improved. Traditional Chinese medicine has rich clinical experience in antiviral treatment. Doctors of all dynasties have summarized a large number of antiviral traditional Chinese medicines and their combinations, providing a valuable experience basis for the research on antiviral treatment of traditional Chinese medicines. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a Chinese medicine composition having broad-spectrum antiviral activity, high safety and small side effects and a preparation method thereof.
[0005] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0006] The Chinese medicine composition is composed of the following raw materials: mung bean, bupleurum, capillaris, isatis root, schisandra chinensis, pig bile powder and cockscomb.
[0007] The above-mentioned Chinese medicine composition is composed of the following raw materials in parts by weight: 13-17 parts of mung beans, 28-32 parts of bupleurum, 28-32 parts of capillaris, 28-32 parts of isatis root, 13-17 parts of schisandra, 2-6 parts of pig bile powder and 48-52 parts of cockscomb.
[0008] The above-mentioned Chinese medicine composition is composed of the following raw materials in parts by weight: 15 parts of mung beans, 30 parts of bupleurum, 30 parts of capillaris, 30 parts of isatis root, 15 parts of schisandra chinensis, 4 parts of pig bile powder and 50 parts of cockscomb.
[0009] The above-mentioned traditional Chinese medicine composition is used in the preparation of antiviral drugs, and the virus is P2V virus, RV virus, CV-A9 virus, CV-B3 virus, RSV virus, VACV_TT virus, EV71 virus, AdV virus, SARS virus, PEDV virus, ZIKA virus, and PV virus.
[0010] The antiviral medicine comes as a powder for oral administration.
[0011] The preparation method of the oral powder comprises the following steps: firstly, mixing mung bean powder and pig bile powder; then, soaking bupleurum, capillaris, isatis root and cockscomb and then boiling them, filtering them after boiling, concentrating the filtrate into an extract, and drying the extract to prepare a dry extract; then, crushing schisandra chinensis and then extracting it with ethanol reflux, and distilling the extract under reduced pressure to recover ethanol to obtain a concentrated extract; finally, mixing the mixture of mung bean powder and pig bile powder, the dry extract and the concentrated extract, stirring them evenly, and crushing them to obtain the powder.
[0012] The above preparation method is carried out according to the following steps:
[0013] <1> Grind the mung beans into fine powder, then sieve to get mung bean powder and set aside;
[0014] <2> Mix the mung bean powder and pig bile powder evenly and set aside;
[0015] <3> Add appropriate amount of water to soak bupleurum, capillaris, isatis root and cockscomb, decoct, concentrate the medicinal liquid into extract, and dry to make dry extract;
[0016] <4> Grind the Schisandra chinensis fruit, and sieve the crushed fruit to obtain Schisandra chinensis coarse powder;
[0017] <5> Put the Schisandra chinensis crude powder into a reflux extraction device, add ethanol solution as a solvent, and heat reflux extraction;
[0018] <6> filtering the extracted Schisandra chinensis mixture, separating the filtrate and the precipitate, performing reduced pressure distillation on the filtrate, recovering ethanol, and obtaining a concentrated extract;
[0019] <7> The mung bean powder is mixed with the pig bile powder mixture, the dry extract and the concentrated extract of Schisandra chinensis, stirred well, dried and crushed into fine powder.
[0020] step <3> Medium: Soak for 30 minutes, add 8 times the amount of water as the raw material, decoct twice, each time for 2 hours.
[0021] step <3> Chinese: The relative density of the extract is 1.36 at 80℃.
[0022] step <5> Medium: The solvent is 75% ethanol solution, and the extraction is carried out under heating reflux for three times, each time for 3 hours, 2 hours and 1 hour respectively.
[0023] In view of the problems existing in current antiviral drugs, the inventor has developed a Chinese medicine composition consisting of the following raw materials: mung bean, bupleurum, capillaris, isatis root, schisandra chinensis, pig bile powder and cockscomb. Studies have shown that the Chinese medicine composition has antiviral effects against a variety of viruses. Compared with the prior art, the present invention has the following outstanding advantages:
[0024] The raw materials of the present invention are all derived from natural plant and animal ingredients. Compared with synthetic antiviral drugs, they usually have lower side effects and toxicity, are safer and more reliable when used for a long time, are lower in cost, more sustainable and affordable, and also have advantages in environmental protection.
[0025] The present invention contains multiple ingredients that can produce synergistic effects to enhance antiviral activity, and can also act on different targets in the virus life cycle to inhibit viral replication, which makes it more difficult for the virus to develop drug resistance and improves the therapeutic effect.
[0026] The present invention can inhibit the infection of multiple viruses at the same time, and therefore has advantages in treating multiple viral infections, and there is no need to use different drugs for different viruses.
[0027] The present invention is developed based on the theory of traditional Chinese medicine, focusing on the overall view and syndrome differentiation and treatment. While treating viral infections, it can also regulate the human immune system and enhance the body's antiviral ability.
[0028] In summary, the Chinese medicine composition of the present invention has a broad-spectrum antiviral activity and has potential in preventing and treating viral infectious diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The present invention is a flow chart of the preparation method of the Chinese medicine composition.
[0030] Figure 2 This is a graph showing the results of an antiviral pharmacodynamics experiment (half effective concentration test and half cytotoxic concentration test) of the traditional Chinese medicine composition of the present invention, wherein: A P2V virus; B RV; C CV-A9 virus; D CV-B3 virus; E RSV virus; FVACV_TT virus; G EV71 virus; H AdV virus; I SARS virus; J PEDV virus; K ZIKA virus; L PV virus.
[0031] Figure 3 This is a graph showing the relative concentrations of the main components of flavonoids in the preparation method of the Chinese medicine composition of the present invention. DETAILED DESCRIPTION
[0032] 1. Preparation of Chinese medicine composition powder
[0033] Formula: 15 parts of mung bean, 30 parts of bupleurum, 30 parts of capillaris, 30 parts of isatis root, 15 parts of schisandra, 4 parts of pig bile powder and 50 parts of cockscomb. (All raw medicinal materials meet the standards of the first edition of the 2020 edition of the Pharmacopoeia of the People's Republic of China)
[0034] Preparation method (such as Figure 1 shown):
[0035] <1> Put the mung beans into a grinder or pulverizer, grind them into fine powder, then sieve to remove the coarse particles to obtain fine and uniform mung bean powder, set aside;
[0036] <2> Mix the mung bean powder and pig bile powder evenly according to the proportion and set aside; when mixing, use clean containers and tools to avoid impurities. The mixed mung bean powder and pig bile powder should be placed in a cool and dry place, avoiding direct sunlight and high temperature;
[0037] <3> Add 8 times the amount of water to soak Bupleurum, Artemisia capillaris, Radix Isatidis and Celosia cristata for 30 minutes, the amount of water added is 8 times the amount of the above raw materials, decoct twice, the first decoction is 2 hours, the second decoction is 2 hours, the two decoctions are combined and concentrated into an extract (relative density is 1.36 at 80°C), and dried to make a dry extract;
[0038] <4> The schisandra fruit is placed in a grinder and crushed into coarse powder at an appropriate speed to increase its surface area, which is conducive to the extraction of effective ingredients; the crushed schisandra fruit should be sieved to ensure that its particle size distribution is uniform, and the coarse schisandra powder is obtained;
[0039] <5> Put the Schisandra chinensis powder into a reflux extraction device, add 75% ethanol solution as a solvent, heat and reflux extraction at a certain temperature (usually near the boiling point) to dissolve the active ingredients in Schisandra chinensis in ethanol; reflux extraction can ensure that the solvent is in full contact with the medicinal materials and improve the extraction efficiency; according to the dissolution rate and extraction difficulty of the active ingredients in Schisandra chinensis, the extraction process is divided into three stages (i.e. three times), with reflux extraction for 3 hours, 2 hours and 1 hour respectively. This helps to fully extract the different components in Schisandra chinensis and improve the extraction efficiency;
[0040] <6> The extracted Schisandra mixture is filtered to separate the filtrate and the precipitate. The filtrate contains the extracted active ingredients, while the precipitate contains impurities and insoluble substances. The filtrates from the three extractions are combined to obtain more extracts. The combined filtrate is subjected to reduced pressure distillation to recover ethanol to obtain a concentrated extract;
[0041] <7> The mung bean powder is mixed with the pig bile powder mixture, the dry extract and the concentrated extract of Schisandra chinensis according to a certain proportion, the mixture is fully stirred, dried and crushed into fine powder, the fine powder is put into a sealed container and stored in a cool and dry place.
[0042] Mechanism of action (speculation): Some ingredients in the present invention can inhibit viral replication, such as schisandra in Schisandrae Chinensis, which can inhibit viral replication, and bile acid in pig bile powder can destroy the lipid envelope of the virus, thereby inhibiting viral replication. Some ingredients in the present invention can enhance the body's immune function, such as Radix Isatidis saponins in Radix Isatidis can stimulate the body to produce interferon, interferon can inhibit viral replication, and saikosaponins in Radix Bupleuri can enhance the body's cellular immune function, thereby inhibiting viral infection. Some ingredients in the present invention have antioxidant effects, can scavenge free radicals, and reduce viral damage to cells, such as Artemisia capillaris flavonoids in Artemisia capillaris can scavenge free radicals and protect cells from viral damage. Some ingredients in the present invention have anti-inflammatory effects, which can reduce the inflammatory response caused by viral infection, such as bile acid in pig bile powder can inhibit the release of inflammatory factors, thereby reducing inflammatory response. Some ingredients in the present invention have heat-clearing and detoxifying effects, which can remove toxins in the body and reduce toxic reactions caused by viral infection, such as mung bean saponins in mung bean can clear heat and detoxify, and reduce toxic reactions caused by viral infection. The various components of the present invention can synergize with each other to enhance the antiviral efficacy. For example, schisandrin in Schisandra chinensis can enhance the antiviral activity of isatis saponins in Radix Isatidis, and bile acid in pig bile powder can enhance the antiviral activity of saikosaponins in Radix Bupleuri.
[0043] 2. Antiviral Pharmacodynamics Experiment
[0044] The following experiments used the Chinese medicine composition powder prepared in the above step 1 as the experimental medicine.
[0045] Test Example 1 Anti-GX_P2V virus (ie P2V) pharmacodynamics experiment
[0046] 1. Half effective concentration (EC50) test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with GX_P2V virus with a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism 8.0.
[0047] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0048] Test Example 2 Anti-VACV_TT Virus Pharmacodynamics Experiment
[0049] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with VACV_TT virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and cultured for 36 hours. Observe under a microscope, collect cell nucleic acids, and quantify viral nucleic acids using qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism8.0.
[0050] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 36 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0051] Test Example 3 Anti-CV-A9 Virus Pharmacodynamics Experiment
[0052] 1. EC50 test: RD cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Cells were infected with CV-A9 virus at a final MOI of 0.001, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0053] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to RD cells was measured by CellTiter-Blue assay. Specifically, RD cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0054] Test Example 4 Anti-ADV-5 virus (ie, AdV) pharmacodynamics experiment
[0055] 1. EC50 test: Hela cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with ADV-5 virus with a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0056] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Hela cells was measured by CellTiter-Blue assay. Specifically, Hela cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0057] Test Example 5 Anti-CV-B3 Virus Pharmacodynamics Experiment
[0058] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with CVB3 virus at a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and cultured for 24 hours. Observed under a microscope, cell nucleic acids were collected, viral nucleic acids were quantified using qRT-PCR, and GAPDH was used for homogenization. The EC50 was analyzed using GraphPad Prism 8.0.
[0059] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 24 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0060] Test Example 6 Anti-PEDV Virus Pharmacodynamics Experiment
[0061] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with PEDV virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and cultured for 36 hours. Observe under a microscope, collect cell nucleic acids, and quantify viral nucleic acids using qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0062] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 36 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0063] Test Example 7 Anti-EV-A71 virus (i.e. EV71) pharmacodynamics experiment
[0064] 1. Half effective concentration (EC50) test: RD cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with EV-A71 virus with a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. The cells were cultured for 24 hours. Observed under a microscope, cell nucleic acids were collected, and viral nucleic acids were quantified by qRT-PCR. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism 8.0.
[0065] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to RD cells was measured by CellTiter-Blue assay. Specifically, RD cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 24 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0066] Test Example 8 Anti-RSV Virus Pharmacodynamics Experiment
[0067] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with RSV virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time, ranging from 10 mg / mL to 0.02 mg / mL, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and quantify viral nucleic acids using qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0068] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then the fluorescence signal was detected with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0
[0069] Test Example 9 Anti-rotavirus (RV) pharmacodynamics experiment
[0070] 1. Half effective concentration (EC50) test: MA-104 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Rotavirus was activated at 37°C for 30 min with trypsin (EDTA-free) (15050-065, Gibco) at a final concentration of 20ug / ml. Cells were infected with porcine rotavirus OSU strain at a final MOI = 0.1, and the infection maintenance solution contained 0.2% BSA (H1130, Solarbio) and 2ug / ml trypsin (EDTA-free). Different concentrations of drugs were added at the same time, with the drug concentration range of 10mg / mL to 0.02mg / mL, and cultured for 36 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism 8.0.
[0071] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to MA-104 cells was measured by CellTiter-Blue assay. Specifically, MA-104 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, 20 μL of Reagent (G8081, Promega) was incubated at 37°C for 1-2 h, and the fluorescence signal was detected with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPadPrism 8.0.
[0072] Test Example 10 Anti-SARS-CoV virus (i.e. SARS) pharmacodynamics experiment
[0073] 1. Half effective concentration (EC50) test: Huh7 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with SARS-CoV virus with a final MOI of 0.1, and different concentrations of drugs were added at the same time. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL of a traditional Chinese medicine, and the concentration was diluted 2 times. After 2 hours of infection, PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the half effective concentration (EC50) was analyzed using GraphPad Prism8.0.
[0074] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Huh7 cells was measured by CellTiter-Blue assay. Specifically, Huh7 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, the supernatant was removed and washed with PBS, and 100 μL of new culture medium was added and 20 μL of each well was added. Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0075] Test Example 11 Anti-ZIKA virus pharmacodynamics experiment
[0076] 1. EC50 test: Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. The cells were infected with ZIKA virus at a final MOI of 0.01, and different concentrations of drugs were added at the same time. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL of a traditional Chinese medicine, and the concentration was diluted 2 times. After 2 hours of infection, the PBS was washed 3 times and the medium containing the same concentration of drugs was added, and cultured for 48 hours. Observe under a microscope, collect cell nucleic acids, and use qRT-PCR to quantify viral nucleic acids. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPadPrism 8.0.
[0077] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs to Vero E6 cells was measured by CellTiter-Blue assay. Specifically, Vero E6 cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10.3 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 48 hours, the supernatant was removed and washed with PBS, and 100 μL of new culture medium was added and 20 μL of each well was added. Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0078] Test Example 12 Anti-PV-1 virus (i.e. PV) pharmacodynamics experiment
[0079] 1. EC50 test: RD cells were pre-seeded in 96-well plates (2×104 cells / well) and cultured overnight. Cells were infected with PV-1 virus at a final MOI of 0.1, and different concentrations of drugs (three traditional Chinese medicines) were added at the same time. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. The cells were cultured for 24 hours. Observed under a microscope, cell nucleic acids were collected, and viral nucleic acids were quantified by qRT-PCR. GAPDH was used for homogenization, and the EC50 was analyzed using GraphPad Prism 8.0.
[0080] 2. Half cytotoxic concentration (CC50) test: The cytotoxicity of drugs (three traditional Chinese medicines) to RD cells was measured by CellTiter-Blue assay. Specifically, RD cells were pre-seeded in 96-well plates (2×104 cells / well), and different concentrations of drugs were added after overnight culture. The drug concentration range was 10 mg / mL to 0.02 mg / mL, and the concentration was diluted 2 times. After incubation for 24 hours, 20 μL of Reagent (Promega, G8081), incubated at 37°C for 1-2 h, and then detected the fluorescence signal with an excitation wavelength of 554 nm and an emission wavelength of 593 nm. The half cytotoxic concentration (CC50) was analyzed using GraphPad Prism 8.0.
[0081] 3. Results of antiviral pharmacodynamics experiments
[0082] like Figure 2 As shown, as the drug concentration increases, the percentage of cell activity gradually decreases, and the percentage of virus inhibition gradually increases. When the drug concentration reaches a certain value, the percentage of cell activity drops to the lowest, and the percentage of virus inhibition reaches the highest. Table 1 shows the experimental data of the Chinese medicine composition against broad-spectrum viruses on 12 different viruses. The data in the table show the half effective concentration (EC50) and half cytotoxic concentration (CC50) of the drug. EC50 is the drug concentration that makes the virus inhibition reach 50%, and CC50 is the drug concentration that reduces the cell activity by 50%. As can be seen from Table 1, the Chinese medicine composition of the present invention has good inhibitory activity against 12 different viruses, and has low toxicity to cells. This shows that the Chinese medicine ointment has high safety and effectiveness.
[0083] Table 1 Pharmacodynamics test results of the Chinese medicine composition of the present invention against 12 viruses
[0084]
[0085] like Figure 3As shown, the horizontal axis is the Chinese name of the main flavonoid components, and the vertical axis is the relative concentration of the main flavonoid components. The components with higher content include 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-deoxy-α-L-mannosyl-(1->2)-[6-deoxy-α-L-mannosyl-(1->6)]-β-D-pyranoside, apigenin, isovitexin, isorhamnetin-3-O-neohesperidin, and narcissin. Most of these components have antioxidant, anti-inflammatory, antibacterial, antiviral and anticancer effects.
Claims
1. A Chinese medicine composition, characterized in that It is composed of the following ingredients: mung bean, bupleurum, capillaris, isatis root, schisandra chinensis, pig bile powder and cockscomb.
2. The Chinese medicine composition according to claim 1, characterized in that The invention is composed of the following raw materials in parts by weight: 13-17 parts of mung beans, 28-32 parts of bupleurum, 28-32 parts of capillaris, 28-32 parts of isatis root, 13-17 parts of schisandra chinensis, 2-6 parts of pig bile powder and 48-52 parts of cockscomb.
3. The Chinese medicine composition according to claim 2, characterized in that The invention is composed of the following raw materials in parts by weight: 15 parts of mung beans, 30 parts of bupleurum, 30 parts of capillaris, 30 parts of isatis root, 15 parts of schisandra chinensis, 4 parts of pig bile powder and 50 parts of cockscomb.
4. Use of the Chinese medicine composition according to claim 1 in the preparation of antiviral drugs, characterized in that: The viruses are P2V virus, RV virus, CV-A9 virus, CV-B3 virus, RSV virus, VACV_TT virus, EV71 virus, AdV virus, SARS virus, PEDV virus, ZIKA virus, and PV virus.
5. The use according to claim 4, characterized in that: The antiviral drug described in claim 1 is an oral powder.
6. The method for preparing the oral powder according to claim 5, characterized in that: First, mix mung bean powder and pig bile powder; then soak bupleurum, artemisia capillaris, isatis root and cockscomb and then boil them, filter after boiling, concentrate the filtrate into an extract, and dry the extract to make a dry extract; then, crush Schisandra chinensis and extract it with ethanol reflux, and distill the extract under reduced pressure to recover ethanol to obtain a concentrated extract; finally, mix the mixture of mung bean powder and pig bile powder, the dry extract and the concentrated extract, stir them evenly, and crush them to obtain the product.
7. The preparation method according to claim 6, characterized in that Follow these steps: <1> Grind the mung beans into fine powder, then sieve to get mung bean powder and set aside; <2> Mix the mung bean powder and pig bile powder evenly and set aside; <3> Add appropriate amount of water to soak bupleurum, wormwood, isatis root and cockscomb, decoct, concentrate the liquid medicine into extract, and dry to make dry extract; <4> Grind the Schisandra chinensis fruit, and sieve the crushed fruit to obtain Schisandra chinensis coarse powder; <5> Put the Schisandra chinensis crude powder into a reflux extraction device, add ethanol solution as a solvent, and heat reflux extraction; <6> filtering the extracted Schisandra chinensis mixture, separating the filtrate and the precipitate, performing reduced pressure distillation on the filtrate, recovering ethanol, and obtaining a concentrated extract; <7> The mung bean powder is mixed with the pig bile powder mixture, the dry extract and the concentrated extract of Schisandra chinensis, stirred well, dried and crushed into fine powder.
8. The preparation method according to claim 7, characterized in that step <3> Medium: Soak for 30 minutes, add 8 times the amount of water as the raw material, decoct twice, each time for 2 hours.
9. The preparation method according to claim 8, characterized in that step <3> Chinese: The relative density of the extract is 1.36 at 80℃.
10. The preparation method according to claim 7, characterized in that: step <5> Medium: The solvent is 75% ethanol solution, and the extraction is carried out under heating reflux for three times, each time for 3 hours, 2 hours and 1 hour respectively.
Citation Information
Patent Citations
Medicine composition for treating chronic hepatitis and preparing method thereof
CN105596517A
